eli lilly tirzepatide trial to Spend $5.3 Billion to Boost Output of Mounjaro and Zepbound Eli Lilly stock soars on

Services like Oana Healths telehealth platform can guide patients in managing these challenges and finding the treatment plan that works best for them

Tirzepatide has been approved for chronic weight management in adults with obesity or overweight conditions in conjunction with a reduced-calorie diet and increased physical activity

"Some of the side effects we found, like nausea, are well known, and that shows that the method is picking up a real signal," says Sharath Chandra Guntuku, Research Associate Professor in Computer and Information Science (CIS) at Penn Engineering and the study's senior author

Consent to publish Not applicable